Enliven Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 22.74 million compared to USD 14.72 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.8 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.47 USD | -1.69% |
|
+4.89% | +55.13% |
24/06 | Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to S&P Pharmaceuticals Select Industry Index | CI |
11/06 | Baird Initiates Enliven Therapeutics With Outperform Rating, $32 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.13% | 1.01B | |
+16.45% | 122B | |
+21.96% | 116B | |
+25.76% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-15.71% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024